A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate and 3 mg Drospirenone in Post-menarchal Female Adolescents for 6 cycles
Latest Information Update: 13 Mar 2024
At a glance
- Drugs Drospirenone/estetrol (Primary)
- Indications Pregnancy
- Focus Adverse reactions; Registrational
- Sponsors Estetra SPRL
- 20 Dec 2023 Status changed from active, no longer recruiting to completed, according to a Mithra Pharmaceuticals media release.
- 20 Dec 2023 According to a Mithra Pharmaceuticals media release, last patient last visit has been completed with data expected in Q2 2024.
- 15 Dec 2023 This study has been completed in Poland, according to European Clinical Trials Database record.